The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.

In 77 percent of patients suffering from a malignant carcinoid syndrome, administration of the somatostatin analog, octreotide (SMS 201-995, Sandostatin) induced clinical improvement coupled with a decrease in 24-hour urinary 5-hydroxyindole acetic acid (5-HIAA). This finding prompted an evaluation...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kvols, L. K., Reubi, J. C., Horisberger, U., Moertel, C. G., Rubin, J., Charboneau, J. W.
Formato: Artigo
Idioma:Inglês
Publicado: Yale Journal of Biology and Medicine 1992
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2589749/
https://ncbi.nlm.nih.gov/pubmed/1364090
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares